Prevention Trials: Their Place in How We Understand the Value of Prevention Strategies

被引:18
|
作者
Colditz, Graham A. [1 ]
Taylor, Philip R. [2 ]
机构
[1] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
[2] NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA
来源
ANNUAL REVIEW OF PUBLIC HEALTH, VOL 31 | 2010年 / 31卷
关键词
durability; adherence; bias; behavior modification; drugs; intention-to-treat; HEALTHY POSTMENOPAUSAL WOMEN; SURGICAL ADJUVANT BREAST; ESTROGEN PLUS PROGESTIN; DESIGN AFFECTS OUTCOMES; CANCER PREVENTION; PUBLIC-HEALTH; COLORECTAL ADENOMAS; ADOLESCENT DIET; BETA-CAROTENE; LUNG-CANCER;
D O I
10.1146/annurev.publhealth.121208.131051
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Several key factors bear on the interpretation of prevention trials and observational studies that inform prevention strategies. These factors include the underlying disease process and aspects of the intervention: sustainability of behavior change, the time course of the intervention within the disease process, dose and duration of exposure needed to effect risk reduction, durability of the impact of intervention, and methodological problems in implementing and interpreting randomized trials and observational studies to evaluate prevention strategies. The question asked through an intent-to-treat analysis of a randomized controlled trial (RCT) differs from that in the observational setting. Furthermore, the long duration necessary to conduct prevention trials and the resulting lack of adherence to therapy can bias results toward the null. A broader range of approaches to evaluate prevention interventions and programs with improved knowledge synthesis and translation to public health practice will speed our progress toward achieving public health and prevention of chronic diseases.
引用
收藏
页码:105 / 120
页数:16
相关论文
共 50 条
  • [1] How Will We Understand Prevention in the 21st Century?
    Thomas P. Gullotta
    Journal of Primary Prevention, 2000, 21 (2) : 145 - 146
  • [2] Hospital Infection Prevention: How Much Can We Prevent and How Hard Should We Try?
    Gonzalo Bearman
    Michelle Doll
    Kaila Cooper
    Michael P. Stevens
    Current Infectious Disease Reports, 2019, 21
  • [3] Hospital Infection Prevention: How Much Can We Prevent and How Hard Should We Try?
    Bearman, Gonzalo
    Doll, Michelle
    Cooper, Kaila
    Stevens, Michael P.
    CURRENT INFECTIOUS DISEASE REPORTS, 2019, 21 (01)
  • [4] Prevention Therapy for Breast Cancer: How Can We Do Better?
    Wood, Marie E.
    Cuke, Melissa
    Bedrosian, Isabelle
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (07) : 1970 - 1972
  • [5] Prevention research strategies
    Kuller, LH
    NUTRITION REVIEWS, 2006, 64 (02) : S2 - S8
  • [6] Measles, mumps, rubella prevention: how can we do better?
    Kauffmann, Florence
    Heffernan, Catherine
    Meurice, Francois
    Ota, Martin O. C.
    Vetter, Volker
    Casabona, Giacomo
    EXPERT REVIEW OF VACCINES, 2021, 20 (07) : 811 - 826
  • [7] The madness of HIV prevention trials
    S McCormack
    Trials, 16 (Suppl 2)
  • [8] A critical analysis of obesity prevention policies and strategies
    Salas, Ximena Ramos
    Forhan, Mary
    Caulfield, Timothy
    Sharma, Arya M.
    Raine, Kim
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2017, 108 (5-6): : E598 - E608
  • [9] Cancer Prevention Strategies for Women
    Tergas, Ana I.
    Wright, Jason D.
    OBSTETRICS AND GYNECOLOGY, 2019, 134 (01) : 30 - 43
  • [10] Applying Tobacco, Environmental, and Dietary-Related Biomarkers to Understand Cancer Etiology and Evaluate Prevention Strategies
    Peterson, Lisa A.
    Balbo, Silvia
    Fujioka, Naomi
    Hatsukami, Dorothy K.
    Hecht, Stephen S.
    Murphy, Sharon E.
    Stepanov, Irina
    Tretyakova, Natalia Y.
    Turesky, Robert J.
    Villalta, Peter W.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (10) : 1904 - 1919